J 2008

Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients

ŠPINAROVÁ, Lenka, Jindřich ŠPINAR, Anna VAŠKŮ, Monika PÁVKOVÁ GOLDBERGOVÁ, Ondřej LUDKA et. al.

Basic information

Original name

Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients

Name in Czech

Genetika humorální a cytokinové aktivace u srdečního selhání a její význam pro stratifikaci rizika pacientů

Authors

ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Anna VAŠKŮ (203 Czech Republic, belonging to the institution), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution) and Jiří VÍTOVEC (203 Czech Republic, belonging to the institution)

Edition

Experimental and Molecular Pathology, USA, The Human Press, 2008, 0014-4800

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.930

RIV identification code

RIV/00216224:14110/08:00026223

Organization unit

Faculty of Medicine

UT WoS

000257725700011

Keywords in English

Genetics;cytokines;chronic hear failure;stratification

Tags

chronic hear failure, cytokines, genetics, stratification

Tags

Reviewed
Změněno: 6/6/2012 08:49, doc. RNDr. Josef Tomandl, Ph.D.

Abstract

ORIG CZ

V originále

Genetics of humoral and cytokine activation in heart failure and its importance for risk stratification of patients. Patients with ischemic heart disease (IHD) and previous MI showed a difference in the distribution of genotype G8002A for endothelin-1: allele G 0.718 and A 0.282 vs those without MI: allele G 0.882 and A 0.118, (p < 0.05). Patients with IHD and DM had allele G in 0.67 and A 0.33, while those without DM had allele G in 0.790 and A in 0.209 (p < 0.03). Patients with IHD and concomitant PAD had allele G in 0.718 and A in 0.282 vs those without PAD allele G in 0.882 and A in 0.118 (p < 0.0004). Patients with dilative cardiomyopathy (DCMP) showed no differences in genotype G8002A and presence of DM or PAD. It might be speculated that in the case of endothelin-1 and TNF alpha in CHF the genetic determination is not important, and plasma concentrations are influenced more by the disease severity. Ischemics with previous MI, concomitant DM or PAD showed more frequently allele A and less often allele G than those without these diseases. A genotype with allele A is associated with higher risk of concomitant diseases.

In Czech

Genetika humorální a cytokinové aktivace u srdečního selhání a její význam pro stratifikaci rizika pacientů. Patients with ischemic heart disease (IHD) and previous MI showed a difference in the distribution of genotype G8002A for endothelin-1: allele G 0.718 and A 0.282 vs those without MI: allele G 0.882 and A 0.118, (p < 0.05). Patients with IHD and DM had allele G in 0.67 and A 0.33, while those without DM had allele G in 0.790 and A in 0.209 (p < 0.03). Patients with IHD and concomitant PAD had allele G in 0.718 and A in 0.282 vs those without PAD allele G in 0.882 and A in 0.118 (p < 0.0004). Patients with dilative cardiomyopathy (DCMP) showed no differences in genotype G8002A and presence of DM or PAD. It might be speculated that in the case of endothelin-1 and TNF alpha in CHF the genetic determination is not important, and plasma concentrations are influenced more by the disease severity. Ischemics with previous MI, concomitant DM or PAD showed more frequently allele A and less often allele G than those without these diseases. A genotype with allele A is associated with higher risk of concomitant diseases.

Links

MSM0021622402, plan (intention)
Name: Časná diagnostika a léčba kardiovaskulárních chorob
Investor: Ministry of Education, Youth and Sports of the CR, Early diagnostics and treatment of cardiovascular diseases
Displayed: 10/11/2024 01:33